Fan Yang1, Jiehua Qiu2, Zeliang Fu3, Yuchen Qiu3, Junrong Luo1, Qingyang Xiao1, Huabin Cao1. 1. Institute of Animal Population Health, College of Animal Science and Technology, Jiangxi Agriculture University, Jiangxi, P.R. China. 2. Department of Vascular Surgery, the Second Affiliated Hospital of Nanchang University, Jiangxi, P.R. China. 3. APT Medical Inc., Hunan, P.R. China.
Abstract
OBJECTIVE: To evaluate the safety and feasibility of a novel stent-graft for thoracic endovascular aortic repair (TEVAR) in a canine model, 9 adult hybrid dogs were used for the experiment. METHODS: All animals were implanted with a novel thoracic aortic stent-graft via femoral artery. Blood sample was collected at pre-operation and 1, 2, 4, 8 and 12 weeks after implantation for hematological examination. Moreover, tissues from randomly selected 4 dogs were subjected to histopathological analysis with the optical microscope after stent-grafts were implanted for 3, 6, 9, and 12 months respectively. The experimental period lasted for more than 2 years. RESULTS: A total of 9 stent-grafts were successfully implanted in the canine thoracic aortas and no migration or deformation occurred. Related indicators of blood routine, inflammatory factors, and immunology changes were not significantly (P>0.05), except the white blood cell (WBC) counts in the first week. Moreover, abnormal morphology was not found in all thoracic aortas via histopathological examination. Additionally, all stent-grafts were patent and did not migrate, and there was no thrombus in the lumens of stent-grafts. CONCLUSION: The novel thoracic aortic stent-graft made in China was safe and feasible for thoracic endovascular aortic repair in a canine model.
OBJECTIVE: To evaluate the safety and feasibility of a novel stent-graft for thoracic endovascular aortic repair (TEVAR) in a canine model, 9 adult hybrid dogs were used for the experiment. METHODS: All animals were implanted with a novel thoracic aortic stent-graft via femoral artery. Blood sample was collected at pre-operation and 1, 2, 4, 8 and 12 weeks after implantation for hematological examination. Moreover, tissues from randomly selected 4 dogs were subjected to histopathological analysis with the optical microscope after stent-grafts were implanted for 3, 6, 9, and 12 months respectively. The experimental period lasted for more than 2 years. RESULTS: A total of 9 stent-grafts were successfully implanted in the canine thoracic aortas and no migration or deformation occurred. Related indicators of blood routine, inflammatory factors, and immunology changes were not significantly (P>0.05), except the white blood cell (WBC) counts in the first week. Moreover, abnormal morphology was not found in all thoracic aortas via histopathological examination. Additionally, all stent-grafts were patent and did not migrate, and there was no thrombus in the lumens of stent-grafts. CONCLUSION: The novel thoracic aortic stent-graft made in China was safe and feasible for thoracic endovascular aortic repair in a canine model.
Aortic dissection (AD) is a life-threatening cardiovascular disease with high
mortality[. Multiple
abnormalities have been suggested to contribute to predisposition for this disease,
mainly including hypertension, degeneration and genetic disorders[. The natural incidence of AD was 0.5-3.2/100.000/yr[, and there are about more than 10 thousand new cases of AD each
year in China[. Meszaros et
al.[ reported that about
50% patients died within 24 hours and 68.2% within the first 2 days after admission.
Besides, the reporting cases of deaths due to aortic abnormalities including AD,
thoracic aortic aneurysm (TAA) and abdominal aortic aneurysm (AAA) have accelerated
more recently[.Traditional surgical management technique for aortic diseases such as AD and TAA is
surgical replacement with a prosthetic graft, whereas high postoperative
complications and mortality have been described. Parodi et al.[ firstly reported that endovascular
stent-graft treatment of AAA in 1991. Dake et al.[ used transluminally placed stent-grafts to treat
descending TAA in 13 patients over a 24-month period. Endovascular stent-graft is
capable of repairing various aortic abnormalities as well as maintaining blood flow
and declining the possibility of aortic rupture. Therefore, thoracic endovascular
aortic repair (TEVAR) by means of stent-graft has turned out to be a more attractive
option than conventional surgical approaches[. However, TEVAR
may result in kinking, endoleak, infolding or even stent-graft migration.
Stent-graft disconformability and disattachment phenomena at the inner aortic arch
radius in juvenile trauma victims have received widespread attention[. Although enormous applications have been found in China,
most of stent-grafts for TEVAR come from import. Some Chinese patients cannot afford
such high medical fees, and the specifications of the commercially available
stent-grafts are unitary, which cannot satisfy the needs of complying with tapering
naturally vessel, leading to high rates of long-term complication of endovascular
stent-graft's distal end. Thus, it is urgent to independently develop a homegrown
stent-graft with various tapers. This evaluation work was carried out to primarily
evaluate the safety and feasibility of a novel thoracic aortic stent-graft designed
by a company in a canine model.
METHODS
Compliance with Ethical Standards
All experimental procedures complied with the criteria in Guide for the Care and
Use of Laboratory Animals and Brazilian Guidelines on Care and Use of Animals
for Scientific and Teaching Purposes, National Council for Animal
Experimentation Control. The institutional ethics committee also approved this
study.
Stent-graft System
The stent-graft, 110 mm in length and 26 mm in diameter, is mainly comprised of
nickel titanium alloy, polyethylene terephthalate and platinum-iridium alloy. It
has characteristics such as good bendability, compliance, adhesion of vessel
wall and low profile. The transportation system and delivery system are mainly
composed of Teflon, polycarbonate and stainless steel, resulting in higher
compliance. Moreover, the minimum size of transportation system is 14 F, while
general products' sizes are 6-8 F. In addition, the external sheath of
transportation system, merely 4.9 mm to 6.1 mm in diameter, can obviously reduce
the damage of blood vessel. The markers on stent-graft are used to ensure
accurate positioning (Figure 1).
Fig. 1
Stent-graft system
Stent-graft system
Animals and Treatments
The non-survival procedures were performed in compliance with national animal
welfare laws. Nine adult hybrid dogs (weight 25 to 35 kg), used in this study,
were derived from social donation after physical examination, vaccination and
disinsectization performed. All animals were fed with special dog food and also
guaranteed free access to water and provided an adequate housing. The dogs were
handled and treated in accordance with strict guiding principles of the National
Institutes of Health for experimental care and use of animals. The implantations
were performed in a month and the experimental period lasted for more than 2
years. The order and time of necropsy are shown in Table 1.
Table 1
Order and time of necropsy of dogs.
Dog
1, 2
3, 4
5, 6
7, 8
9
Time of necropsy(after surgery)
3 months
6 months
9 months
12 months
> 12 months
Order and time of necropsy of dogs.
Operation
The operation was performed at Second Affiliated Hospital of Nanchang University.
Dogs were given antibiotics for 3 days, 12 hours of fasting and water
deprivation was carried out before surgery. The dogs were given a hypodermic
injection of atropine sulfate (0.01 mg/kg) and etamsylate (10 mg/kg),
respectively. Anesthesia was followed by intravenous propofol (6 mg/kg).The diameter of thoracic aorta was evaluated through the femoral artery. The
heparinsaline and contrast media were injected. And then, the loach guide wire
and the pigtail catheter were inserted via common femoral artery. The distal end
of the pigtail catheter should reach the position of ascending thoracic aorta.
Angiography was conducted to measure the diameter of thoracic aorta (Figure 2). Afterwards, 260 cm in length with
curved super-stiff guide wire were sent to the specific location of aortic arch
via the pigtail catheter, and then the pigtail catheter and short needle sheath
were extracted. Subsequently, the stent-graft system was sent to the desired
position via the super-stiff guide wire. Finally, the stent-graft was unfolded
and affixed to the vascular wall when it reached the desired position.
Angiography was repeated to evaluate the effect of implantation (Figure 2).
Fig. 2
Angiography. (A) Preoperative angiography image. (B) The delivery
system reached the present position. (C) The release of stent-graft
firstly. (D) Postoperative angiography image.
Angiography. (A) Preoperative angiography image. (B) The delivery
system reached the present position. (C) The release of stent-graft
firstly. (D) Postoperative angiography image.
Blood Collection
Blood samples were collected from 9 dogs preoperatively and 1, 2, 4, 8 and 12
weeks after implantation. Two milliliters of blood collected via cephalic vein
was used for the examination of blood routine. The remaining blood was allowed
to clot, incubated at 37°C for 2 hours and the serum was obtained by
centrifugation at 1000 g for 5 minutes at 4°C. Then the serum was stored at
-20°C until analyzed for the examination of inflammatory factors and
immunological indexes.
Sacrifice and Tissue Collection
A complete necropsy was performed on 8 dogs at clinical veterinary medicine
laboratory in the College of Animal Science and Technology Jiangxi Agricultural
University. Histopathological examination was carried out on 4 dogs randomly
selected 3, 6, 9 and 12 months after implantation. The thoracic aorta was
dissected and washed with saline, then fixed in 10% neutral buffered formalin
(3-5 days). Formalin-fixed samples were routinely processed, embedded in
paraffin, sectioned at 5 µm, stained with hematoxylin and eosin
(H&E), and pathological sections were observed using an optical microscope
and photographs were taken.
Statistical Analysis
The results were presented as mean ± SD. The statistical analysis included
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA), Student's t-test, GraphPad
Prism 5.0 (GraphPad Inc., La Jolla, CA, USA). A P value of less
than 0.05 was considered significant.
RESULTS
No animal was killed during this experiment, except intentional sacrifice.
Furthermore, no abnormality was found in habits and lifestyle on all animals before
necropsy. The ninth animal was kept alive for late follow-up and it is showing good
evolution.
Results of the Blood Routine
As shown in Figure 3, white blood cell (WBC)
counts at the first week after implantation were significantly increased
(P<0.05), in comparison with those at preoperative
period, while there was no significant difference (P>0.05)
among preoperative days and the other days (Figure
3A). Changes in red blood cell (RBC) counts, hemoglobin (Hb) levels
and platelet (PLT) counts were not significant (P>0.05)
among pre- and postoperative periods, and all indicators were kept in normal
range in the experimental period (Figures
3B, C and D).
Fig. 3
Blood routine indexes at pre- and 1, 2, 4, 8 and 12 weeks after
implantation. Panels A-D show changes of WBC counts, RBC counts, Hb
levels and PLT counts, respectively.
*Donate significant difference (P<0.05). Data are the means
± SEM (n=9).
Blood routine indexes at pre- and 1, 2, 4, 8 and 12 weeks after
implantation. Panels A-D show changes of WBC counts, RBC counts, Hb
levels and PLT counts, respectively.*Donate significant difference (P<0.05). Data are the means
± SEM (n=9).
Results of Inflammatory Factors
As shown in Figure 4, the levels of tumor
necrosis factor-α (TNF-α) (Figure
4A) and C-reactive protein (CRP) (Figure 4B) were kept in normal range during the experimental period
and there was no significant difference (P>0.05) among pre-
and postoperative periods.
Fig. 4
Inflammatory factors at pre- and1, 2, 4, 8 and 12 weeks after
implantation. Panels A-B show changes of levels of TNF-α and
CRP, respectively.
Data are the means ± SEM (n=9).
Inflammatory factors at pre- and1, 2, 4, 8 and 12 weeks after
implantation. Panels A-B show changes of levels of TNF-α and
CRP, respectively.Data are the means ± SEM (n=9).
Results of Immunological Indexes
The changes of immunological indexes are shown in Figure 5. No significant difference (P>0.05) in
the levels of complement-3 (C3), immunoglobulin G (IgG) and immunoglobulin M
(IgM) among pre- and post-operative periods were observed and all indicators
were kept in normal range (Figures 5A,
B and C).
Fig. 5
Immunological indexes at pre- and 1, 2, 4, 8 and 12 weeks after
implantation. Panels A-C show changes of levels of C3, IgG and IgM,
respectively.
The data are the means ± SEM (n=9).
Immunological indexes at pre- and 1, 2, 4, 8 and 12 weeks after
implantation. Panels A-C show changes of levels of C3, IgG and IgM,
respectively.The data are the means ± SEM (n=9).
Autopsy Findings
All stent-grafts were patent and did not migrate. As shown in Figure 6, the inner surface of stent-graft
was smooth, suggesting satisfactory neointimal coverage and the adventitia
appeared essentially normal. Additionally, there was no thrombus in the lumens
of stent-grafts. Endothelialization was found in the thoracic aorta implanted
with stent-grafts, and perivascular erosion was not observed.
Fig. 6
Thoracic aorta implanted with stent-graft.
Thoracic aorta implanted with stent-graft.
Histopathological Examination
The histopathological results of thoracic aorta with no stent-graft are shown in
Figure 7. All the tissue slices showed
normal morphology. No inflamed cells (mononuclear cell, macrophage, etc.) and
degeneration or necrosis were found. Additionally, the histopathological results
in the thoracic aorta implanted with stent-graft are shown in Figure 8. All the tissue slices showed no
abnormal sign. Abnormal cells and thoracic aorta thickening were not
observed.
Fig. 7
Histopathological changes in thoracic aorta with no stent-graft. (A)
Thoracic aorta of 3 months after implantation. (B) Thoracic aorta of
6 months after implantation. (C) Thoracic aorta of 9 months after
implantation. (D) Thoracic aorta of 12 months after implantation.
Magnification, ×100.
Fig. 8
Histopathological changes in thoracic aorta implanted with
stent-graft. (A) Thoracic aorta of 3 months after implantation. (B)
Thoracic aorta of 6 months after implantation. (C) Thoracic aorta of
9 months after implantation. (D) Thoracic aorta of 12 months after
implantation. Magnification, ×100.
Histopathological changes in thoracic aorta with no stent-graft. (A)
Thoracic aorta of 3 months after implantation. (B) Thoracic aorta of
6 months after implantation. (C) Thoracic aorta of 9 months after
implantation. (D) Thoracic aorta of 12 months after implantation.
Magnification, ×100.Histopathological changes in thoracic aorta implanted with
stent-graft. (A) Thoracic aorta of 3 months after implantation. (B)
Thoracic aorta of 6 months after implantation. (C) Thoracic aorta of
9 months after implantation. (D) Thoracic aorta of 12 months after
implantation. Magnification, ×100.
DISCUSSION
The application of endovascular repair by means of stent-graft has been demonstrated
to be a safe and effective treatment for various diseases of thoracic
aorta[. This technology has been widely applied in
China. The demand for stent-graft is on the increase due to the huge population of
patients in China who are suffering from aorta diseases. However, most of
stent-grafts in China rely on imports now. Moreover, it is difficult to afford the
medical fees for people because China is a developing country. Besides, the
specifications of these stent-grafts are unitary, which cannot satisfy the needs of
complying with tapering naturally vessel, leading to high rates of long-term
complication of endovascular stent-graft's distal end. It is urgent to independently
design an effective homegrown stent-graft, which has various tapers and can decline
the rates of long-term complication of endovascular stent-graft's distal end. The
stent-graft used in our study has good bendability, compliance, adhesion of vessel
wall and low profile, and can obviously reduce the damage of blood vessel, which
could solve the deficiencies in general products.In this study, experimental animals were used to evaluate the safety and feasibility
of the stent-graft because it was convenient for real-time observation. Dogs (weight
25 to 35 kg) were adopted in this research, as the diameter of their artery and its
hemodynamics are approximate to human. Furthermore, their tolerance is strong enough
to survive long hours of anesthesia and surgery. Canine fibrinolytic system of is
more active than the human[,
and their mortality rate and postoperative complications are much lower than other
animals.Aortic abnormalities such as AD and TAA are harmful diseases with high mortality in
emergencies. Endovascular stent-grafts not only could repair various aortic
abnormalities, but also maintain blood flow and decline the possibility of aortic
rupture. However, there were plenty of problems of early first-generation
stent-grafts, such as vascular injury, ascending aortic dissection or aortic
penetration from struts, stroke with insertion, graft collapse, endovascular leaks,
graft material failure, continued aneurysm expansion or rupture, and migration or
kinking[. Besides,
inflammation and rejection are also worth of concerning in complication. In this
study, the obvious increase of WBC counts at the first week after the implantation,
while there was no remarkable difference in other days, reflected inflammation
caused by surgery, which could also be demonstrated by the results of inflammation
factor. However, it had been improved significantly after using antibiotic. The
results of immunological indexes revealed that rejection was not obvious in
vivo. Some innovative studies on endovascular repair in animal model
have been conducted to study aortic diseases, but they were short-term
studies[. All dogs had stent-grafts implanted successfully
in this study. Focus should be attached to the materials of stent-graft in
implantation, as well as the importance of surgery itself. Multiple reasons have
been confirmed to contribute to fail, mainly including anesthesia, intubation
failure, hemorrhage, postoperative infection and improper nursing care.In our study, the autopsy results showed that the stent-graft could fit the vessel
wall of thoracic aorta well. The formation of intima on the inner surface of the
bare stent and complete endothelialization of stent-graft surface were observed. The
histopathological results also showed that neointima had formed and adventitia
appeared essentially normal. The results demonstrated that the stent-graft had high
histocompatibility and sealability and had not induced inflammation and
calcification, which were consistent with majority relevant reports[. Additionally, the experimental period was more than 2
years, so that the long-term dynamic changes could be distinctly observed, which
further demonstrated the safety of stent-graft.In short, further research is still needed before final clinical application.
CONCLUSION
In the present study, the thoracic aortic stent-graft made in China was safe and
feasible for TEVAR in a canine model.
Abbreviations,
acronyms & symbols
AAA
= Abdominal aortic
aneurysm
AD
= Aortic dissection
C3
= Complement-3
CRP
= C-reactive protein
Hb
= Hemoglobin
H&E
= Hematoxylin and
eosin
IgG
= Immunoglobulin G
IgM
= Immunoglobulin M
PLT
= Platelet
RBC
= Red blood cell
TAA
= Thoracic aortic
aneurysm
TEVAR
= Thoracic endovascular
aortic repair
TNF-α
= Tumor necrosis
factor-α
WBC
= White blood cell
Authors' roles &
responsibilities
FY
Design and draft of the work; final
approval of the manuscript version to be published
JQ
Draft of the work and review it critically
for important intellectual content; final approval of the manuscript
version to be published
ZF
Contributions to the analysis and
interpretation of data for the work; final approval of the
manuscript version to be published
YQ
Contributions to the analysis and
interpretation of data for the work; final approval of the
manuscript version to be published
JL
Calibration; final approval of the
manuscript version to be published
QX
Calibration; final approval of the
manuscript version to be published
HC
Design and draft of the work; final
approval of the manuscript version to be published
Authors: Nicholas T Kouchoukos; Joseph E Bavaria; Joseph S Coselli; Ralph De la Torre; John S Ikonomidis; Riyad C Karmy-Jones; Robert Scott Mitchell; Richard J Shemin; David Spielvogel; Lars G Svensson; Grayson H Wheatley Journal: J Thorac Cardiovasc Surg Date: 2006-03 Impact factor: 5.209
Authors: Davy Cheng; Janet Martin; Hani Shennib; Joel Dunning; Claudio Muneretto; Stephan Schueler; Ludwig Von Segesser; Paul Sergeant; Marko Turina Journal: J Am Coll Cardiol Date: 2010-03-09 Impact factor: 24.094
Authors: Lars G Svensson; Nicholas T Kouchoukos; D Craig Miller; Joseph E Bavaria; Joseph S Coselli; Michael A Curi; Holger Eggebrecht; John A Elefteriades; Raimund Erbel; Thomas G Gleason; Bruce W Lytle; R Scott Mitchell; Christoph A Nienaber; Eric E Roselli; Hazim J Safi; Richard J Shemin; Gregorio A Sicard; Thoralf M Sundt; Wilson Y Szeto; Grayson H Wheatley Journal: Ann Thorac Surg Date: 2008-01 Impact factor: 4.330
Authors: Sang-Pil Kim; Han Cheol Lee; Tae Sik Park; Jin Hee Ahn; Hye-Won Lee; Jong-Ha Park; Junhyok Oh; Jung Hyun Choi; Kwang Soo Cha Journal: J Korean Med Sci Date: 2015-03-19 Impact factor: 2.153